Purpose: To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen) in patients with diabetic macular oedema (DMO).
Methods: We conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best-corrected visual acuity (BCVA), of eyes with DMO treated with intravitreal pegaptanib sodium. Moreover, we evaluated the foveal transverse photoreceptor (PR) band integrity in the OCT images at the time of the last follow-up visit.
Results: Sixty-three eyes of 48 patients with a minimum of 6 months of follow-up were included for analysis. Intravitreal pegaptanib was found to produce significant improvements in mean BCVA (p = 0.019) and reductions in mean central macular thickness (CMT) (p < 0.001) as soon as the 6-week follow-up. Most eyes (60/63) required a mean of 3.03 +/- 0.9 repeated treatments, over a mean follow-up period of 6.7 +/- 1.2 months, to achieve significant improvements in mean BCVA (p < 0.001) and mean CMT (p < 0.001). In our series, the lower visual acuities tended to congregate in the group with the less-defined PR band (p < 0.001) and the lower CMT tended to congregate in the group with the best-defined PR band (p = 0.04), even though the higher CMT did not tend to congregate in the group with the less-defined PR band.
Conclusion: Our findings demonstrate that selective inhibition by intravitreal pegaptanib sodium of vascular endothelial growth factor (VEGF)-165 may produce a clinically meaningful and statistically significant benefit in the treatment of DMO.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1755-3768.2009.01580.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview.
Curr Diabetes Rev
April 2024
Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, the Nilgiris, Tamil Nadu, India.
The discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor.
View Article and Find Full Text PDFOcular and systemic vascular endothelial growth factor ligand inhibitor use and nephrotoxicity: an update.
Int Urol Nephrol
August 2024
Department of Nephrology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
Tumor growth is intricately linked to the process of angiogenesis, with a key role played by vascular endothelial growth factor (VEGF) and its associated signaling pathways. Notably, these pathways also play a pivotal "housekeeping" role in renal physiology. Over the past decade, the utilization of VEGF signaling inhibitors has seen a substantial rise in the treatment of diverse solid organ tumors, diabetic retinopathy, age-related macular degeneration, and various ocular diseases.
View Article and Find Full Text PDFA real-world disproportionality analysis of anti-VEGF drugs from the FDA Adverse Event Reporting System.
Expert Opin Drug Saf
March 2024
School of Medical Information and Engineering, Guangdong Pharmaceutical University, Guangzhou, China.
Article Synopsis
- The study analyzed the relationship between anti-VEGF drugs and adverse events (AEs) using data from the FDA Adverse Event Reporting System over a 17-year period.
- Five anti-VEGF drugs were linked to various ocular disorders, with pegaptanib and ranibizumab also showing connections to cardiac issues.
- Notably, ranibizumab exhibited the highest rates of both cardiac and central nervous AEs compared to the other drugs, suggesting the need for awareness of systemic symptoms post-injection.
[The population affected by neovascular age-related macular degeneration and treated with anti-Vegf through Italian administrative healthcare data.].
Recenti Prog Med
July 2023
Fondazione Ricerca e Salute (ReS), Roma.
Introduction: The neo-vascular age-related macular degeneration (nAmd) is a frequent cause of vision loss, although the intravitreal (Ivt) injections of anti-Vegf (vascular endothelial growth factor) have improved functional outcomes. This study has assessed the healthcare and economic burden on the Italian national health service (Inhs) for patients with nAmd and new users of anti-Vegf.
Methods: From the database of Fondazione Ricerca e Salute (ReS), people aged ≥55 and with an in-hospital diagnosis of nAmd and/or an injection of anti-Vegf (aflibercept, ranibizumab, pegaptanib; index date) in 2018 are selected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!